Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Anna Pellat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6024-4830; OpenAlex author ID A5002979022. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2022: 4 papers · 2023: 1 paper · 2024: 1 paper, 1 trial · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  2. Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomography. Co-author DOI 10.1177/08465371261426959↗
  3. End-of-life care for patients with pancreatic cancer in France: a nationwide population-based cohort study. Co-author DOI 10.1177/17588359251320731↗
  4. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  5. Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. Co-author DOI 10.1177/08465371221124927↗
  6. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? First author DOI 10.1016/j.esmoop.2022.100638↗
  7. Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years. Co-author DOI 10.1093/oncolo/oyac156↗
  8. Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment. Co-author DOI 10.3390/cancers14164062↗
  9. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Co-author DOI 10.3390/cancers14246179↗

Trials 1

  1. Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy Principal investigator NCT07243288↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Romain Coriat · 5 shared papers, 2022–2026 · strength 1.03
  2. Ugo Marchèse · 4 shared papers, 2022–2026 · strength 0.83
  3. Maxime Barat · 3 shared papers, 2022–2026 · strength 0.60
  4. Philippe A. Soyer · 3 shared papers, 2022–2026 · strength 0.60
  5. Philippe Ravaud · 2 shared papers, 2022 · strength 0.49
  6. Julien Taı̈eb · 2 shared papers, 2024–2026 · strength 0.38
  7. David Tougeron · 2 shared papers, 2024–2026 · strength 0.38
  8. Marwa Alkatheeri · 1 shared paper, 2026 · strength 0.27
  9. Thị Thùy Linh Nguyễn · 1 shared paper, 2026 · strength 0.27
  10. Mehdi El Amrani · 1 shared paper, 2025 · strength 0.23
  11. Laurent Boyer · 1 shared paper, 2025 · strength 0.23
  12. Carole Vitellius · 1 shared paper, 2026 · strength 0.22
  13. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  14. Frédéric Di Fiore · 1 shared paper, 2026 · strength 0.22
  15. Côme Lepage · 1 shared paper, 2026 · strength 0.22
  16. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  17. Jean‐Baptiste Bachet · 1 shared paper, 2026 · strength 0.22
  18. Maxime Rémond · 1 shared paper, 2022 · strength 0.20
  19. Christophe Cassinotto · 1 shared paper, 2023 · strength 0.18
  20. Elliot K. Fishman · 1 shared paper, 2023 · strength 0.18
  21. Linda Chi Hang Chu · 1 shared paper, 2023 · strength 0.18
  22. Jeannie M'Baloula · 1 shared paper, 2024 · strength 0.16
  23. Jean‐Frédéric Blanc · 1 shared paper, 2024 · strength 0.16
  24. Marie Müller · 1 shared paper, 2024 · strength 0.16
  25. Anthony Turpin · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.